Access cutting-edge pulmonary arterial hypertension treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this San Francisco location
Preparing your pre-screening questions…
Access pulmonary arterial hypertension specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related pulmonary arterial hypertension treatment provided free
Check if you qualify for this pulmonary arterial hypertension clinical trial in San Francisco, CA
No-Cost Study Care
Local to San Francisco
Convenient for CA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH are treated according to recommended guidelines, and to see if there are certain factors that can lead to better or worse outcomes. PHAR will include information about people with PAH and CTEPH in the U.S. who are seen at participating PHA-accredited PH Care Centers. PHAR contains data about patient care and outcomes. Specifically, data in the PHAR includes information on diagnosis; clinical status; socioeconomic status; diagnosis test results; body size; treatment information; interest in participating in clinical trials; family health and social history; and information about smoking, alcohol, or drug use. Participants are followed over time, and provide updates such as changes in therapy, how often participants need to go to the hospital, and survival. Such information may help healthcare providers provide better care.
Sponsor: Pulmonary Hypertension Association, Inc.
Yes, this clinical trial (NCT04071327) has an active research site in San Francisco, CA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for pulmonary arterial hypertension treatment options in San Francisco, CA, this clinical trial (NCT04071327) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pulmonary arterial hypertension specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all pulmonary arterial hypertension clinical trials near you to find additional studies recruiting in your area.
See all hypertension clinical trials recruiting in San Francisco — not just this study.
Browse Hypertension Trials in San Francisco →